LIGHTNING RELEASES: Edmonton, Alberta (1/28/2014)– Innovotech Inc. (TSX-V: IOT), an innovator focused on providing new and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms, is pleased to announce the successful completion of a mastitis susceptibility test project for dairy cows, facilitated by Advanced Foods and Materials (AFM) Canada.
“Mastitis is the most costly bacterial problem in the dairy industry. As with most chronic infections the bacteria responsible are in a difficult to eradicate biofilm state.” said Dr. Amin Omar, General Manager. “Innovotech has developed susceptibility tests against biofilms that can recommend appropriate treatment for an infection. In samples taken from infected cows, Innovotech’s mastitis test identified 97% of the time an antibiotic treatment that killed these hard to eliminate biofilm forming bacteria. This means that a veterinarian can prescribe antibiotics that have a high probability for success the first time, hastening recovery, saving money, and reducing the opportunity for development of resistance.” “The application of the susceptibility test in a select group of dairy herds will establish its benefits for all to see and should eventually lead to routine use of the Innovotech test technology.”
About Innovotech Inc – Innovotech Inc. is an innovator focused on providing new and practical solutions to problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of problems in human, animal and plant health as well as in such varied areas as pipeline corrosion, fuel or paper production and municipal water or waste facilities. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.
For more information contact:
Dr. Amin Omar, General Manager Innovotech Inc.
Telephone: 780.448.0585 ext 221
Connect with us:
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.